CA2413906A1 - Combinaisons de carboxyalkylether et d'inhibiteur de l'acat - Google Patents

Combinaisons de carboxyalkylether et d'inhibiteur de l'acat Download PDF

Info

Publication number
CA2413906A1
CA2413906A1 CA002413906A CA2413906A CA2413906A1 CA 2413906 A1 CA2413906 A1 CA 2413906A1 CA 002413906 A CA002413906 A CA 002413906A CA 2413906 A CA2413906 A CA 2413906A CA 2413906 A1 CA2413906 A1 CA 2413906A1
Authority
CA
Canada
Prior art keywords
pharmaceutically acceptable
phenyl
pharmaceutical composition
acat inhibitor
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002413906A
Other languages
English (en)
Inventor
Bruce Jeffrey Auerbach
Donna Lee Zobel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2413906A1 publication Critical patent/CA2413906A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte sur une préparation pharmaceutique comportant: un carboxyalkyléther qui abaisse le niveau des triglycérides et du LDL et augmente celui du HDL; et un inhibiteur de l'ACAT améliorant les dyslipidémies chez les mammifères, ladite préparation s'avère donc utile pour traiter les dyslipidémies et les syndromes ischémiques, et prévenir ou retarder l'apparition des crises cardiaques. Lesdits carboxyalkyléthers présentent la formule (I) dans laquelle: Y¿1? et Y¿2? comportent COOH, R¿1?, R¿2?, R¿3?, et R¿4? peuvent être alkyle, et n et m sont des entiers de 2 à 9, tandis que les inhibiteurs de l'ACAT présentent la formule (II) dans laquelle: R est H, X est O, R¿1? et R¿2? sont phényle substitué, et Y est alkylène.
CA002413906A 2000-06-07 2001-05-08 Combinaisons de carboxyalkylether et d'inhibiteur de l'acat Abandoned CA2413906A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21005600P 2000-06-07 2000-06-07
US60/210,056 2000-06-07
PCT/US2001/014804 WO2001093845A2 (fr) 2000-06-07 2001-05-08 Combinaisons de carboxyalkylether et d'inhibiteur de l'acat

Publications (1)

Publication Number Publication Date
CA2413906A1 true CA2413906A1 (fr) 2001-12-13

Family

ID=22781424

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002413906A Abandoned CA2413906A1 (fr) 2000-06-07 2001-05-08 Combinaisons de carboxyalkylether et d'inhibiteur de l'acat

Country Status (14)

Country Link
EP (1) EP1292363A2 (fr)
JP (1) JP2003535125A (fr)
AR (1) AR034255A1 (fr)
AU (1) AU2001263003A1 (fr)
BR (1) BR0111428A (fr)
CA (1) CA2413906A1 (fr)
GT (1) GT200100106A (fr)
MX (1) MXPA02010762A (fr)
PA (1) PA8518601A1 (fr)
PE (1) PE20020265A1 (fr)
SV (1) SV2002000466A (fr)
TN (1) TNSN01085A1 (fr)
UY (1) UY26752A1 (fr)
WO (1) WO2001093845A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7387236B2 (en) 2001-10-09 2008-06-17 Delaware Capital Formation, Inc. Dispensing of currency

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ505761A (en) * 1998-01-28 2003-08-29 Warner Lambert Co Method for treating alzheimer's disease using plasma-triglceride level-lowering agents or agents that interfer with cholesterol ester synthesis

Also Published As

Publication number Publication date
MXPA02010762A (es) 2003-03-10
WO2001093845A3 (fr) 2002-10-10
GT200100106A (es) 2002-05-20
WO2001093845A2 (fr) 2001-12-13
AR034255A1 (es) 2004-02-18
PA8518601A1 (es) 2002-07-30
BR0111428A (pt) 2003-06-10
AU2001263003A1 (en) 2001-12-17
UY26752A1 (es) 2001-07-31
SV2002000466A (es) 2002-04-03
TNSN01085A1 (en) 2005-11-10
JP2003535125A (ja) 2003-11-25
EP1292363A2 (fr) 2003-03-19
PE20020265A1 (es) 2002-04-19

Similar Documents

Publication Publication Date Title
ES2279526T3 (es) Metodo y composicion farmaceutica para regular la concentracion de lipidos.
RU2363458C2 (ru) Комбинированная лекарственная терапия для лечения ожирения
JP2000515526A (ja) Ｍｔｐ阻害剤と他のコレステロール低下薬を組合せて使用する、血清脂質レベルの降下方法
JP2010510973A (ja) 心筋組織の壊死を処置するためのホスホエノールピルビン酸誘導体の使用
JPH04225916A (ja) 脂血障害の治療用組成物
JP2006508995A (ja) 血清トリグリセリド値を低下させるためのＰＰＡＲαアゴニスト及びメトホルミンの使用
CA2413906A1 (fr) Combinaisons de carboxyalkylether et d'inhibiteur de l'acat
US20040072903A1 (en) Carboxyalkylether-acat inhibitors combinations
ES2300750T3 (es) Uso combinado de un fibrato y orlistat para el tratamiento de la obesidad.
JP6454436B1 (ja) ペマフィブラートを含有する医薬
AU2019315823A1 (en) New use of carbamate beta phenylethanolamine analogues for enhancing intracellular clearance of ldl cholesterol and for combining therapy with statins to enhance the efficacy and reduce adverse effects
JP2616845B2 (ja) システノール酸又はその胆汁酸抱合体を含有する血中コレステロール低下剤
WO2006011495A1 (fr) Remede pour l'hypercholesterolemie et/ou l'hypertriglyceridemie
CA2030209A1 (fr) Agents therapeutiques
JP7418502B2 (ja) 非常に速い皮膚及び膜浸透速度を有するｎｓａｉａプロドラッグ及びその新規医薬使用
WO2005112944A1 (fr) Médicament pour la prévention ou le traitement du diabète
WO2008015763A1 (fr) Formulation médicamenteuse contenant un médicament fibrate et procédé pour la produire
JP2006225263A (ja) 腎疾患予防・治療剤
CA2233558C (fr) Procede et composition pharmaceutique visant a reguler la concentration lipidique
US20060293218A1 (en) Salicylate therapeutic compound and process for controlled delivery thereof
WO1994012166A1 (fr) Agents therapeutiques pour le traitement de la cachexie
WO2005117853A1 (fr) Agent thérapeutique pour l'hyperlipémie et agent thérapeutique pour le diabète

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead